What Closamectin Treats: Main Uses and Benefits

Closamectin is generally used for mixed parasitic infestations in livestock, applied across domains where additional symptomatic support is needed. The product is indicated for the treatment of mixed trematode (fluke) and nematode or arthropod infestations, which generally assists with addressing multiple threats concurrently, contributing to improved comfort where animals are exposed to diverse parasitic challenges.

The medicine is relevant for easing symptoms associated with conditions involving internal systemic discomfort (e.g., related to trematode and nematode activity) and external irritative states (e.g., related to arthropod burdens). It helps address symptom clusters such as symptoms related to systemic imbalance (diarrhoea, weight loss, respiratory distress), as well as symptoms related to inflammatory or irritative states (intense irritation and discomfort). This is often used in scenarios requiring simultaneous symptomatic assistance against multiple parasite groups.

“This treatment supports an approach to parasite control and contributes to easing the overall symptom load on the herd.”

This use is also relevant for helping manage more complex conditions, such as those involving symptoms linked to organ-specific functional stress, supporting general well-being during symptomatic phases.

Regulatory References

1. Veterinary Medicines Directorate Summary of Product Characteristics

Official Population Eligibility and Restrictions

Closamectin is strictly authorized for use only in its designated target animal species: cattle (for both Pour-On and Injection formulations) and sheep (for the Injection formulation). Official regulatory documents establish clear boundaries for who must not receive the medicine.

Contraindicated Populations

Use is contraindicated for any animal producing milk intended for human consumption, including during the dry period. This prohibition also extends to heifers intended to produce milk during the last trimester of pregnancy. Additionally, animals with a known hypersensitivity to Ivermectin, Closantel, or any product excipients are absolutely excluded from treatment.

Eligibility-Related Restrictions

Specific conditions limit use. The injection formulation must not be administered intravenously or intramuscularly. The Pour-On solution must not be applied to skin areas with lesions, mange, or contamination. Regulators also advise against administering the product when certain parasitic larvae (Hypoderma) are localized in high-risk areas, such as the spinal canal or periaesophagic region, due to potential adverse reactions. While no official minimum age is listed as a contraindication, careful bodyweight assessment is required for safe administration.

Interactions with other medicines and products

The interaction profile for Closamectin (Ivermectin and Closantel) is defined by official warnings and restrictions documented in government regulatory labels, focusing on specific co-administration risks.

Interaction Scope and Restrictions

The regulatory profile mandates a formal restriction against co-administration with chlorinated compounds as a necessary safety measure. Additionally, regulatory authorities document a specific pharmacodynamic interaction risk where Ivermectin, one of the active components, increases the effects of co-administered GABA agonists.

Interaction Classifications

The interaction structure is defined by these two key constraints and the finding that there are no official restrictions listed regarding interactions with food, alcohol, or herbal products in the official product labeling.

Closamectin is a fixed-dose combination containing ivermectin and closantel, each targeting distinct biological pathways. Ivermectin, a macrocyclic lactone, functions as an agonist at ligand-gated chloride ion channels found in invertebrate nerve and muscle cells, particularly the glutamate-gated chloride channels ( GluCl) . Binding causes an increase in the cell membrane's permeability to chloride ions ( Cl^-) and subsequent hyperpolarization of the cell membrane. This hyperpolarization inhibits neural signal transmission, resulting in flaccid paralysis and systemic motor dysfunction in susceptible organisms. Closantel, a salicylanilide, functions as an uncoupler of oxidative phosphorylation in the mitochondria of target organisms, selectively accumulating in the serum due to high plasma protein binding. As a hydrogen ionophore, it disrupts the proton gradient across the inner mitochondrial membrane, inhibiting adenosine triphosphate ( ATP) synthesis. This intracellular energy depletion results in suppressed motility and impaired metabolic processes. The dual mechanism of action modulates both neuromuscular and energy production systems in target invertebrate species.

How to Use Closamectin: Official Administration Guidelines

Closamectin is administered based on two distinct official formulations and routes: subcutaneous injection or topical pour-on. This antiparasitic combination is strictly dosed according to the animal's measured bodyweight to ensure the delivery of the label-specified concentrations of Ivermectin and Closantel per kilogram.

Official Dosing and Frequency Patterns

The standard administration pattern is a single, one-off treatment for the management of mixed parasitic infestations. Timing is generally determined by epidemiological factors and customized for the specific farm setting. Only one distinct use case—the treatment of Sheep Scab—requires a deviation from the single dose, mandating a follow-up injection of an ivermectin-only product seven days after the initial Closamectin dose to eliminate mites.

Administration Requirements

Procedurally, the official instructions require accurate bodyweight measurement before use for all animals to prevent under- or over-dosing. For the injectable form, the 10 mL volume limit per site means any excess must be administered at a separate location within the neck. For pregnant or lactating non-dairy animals, the product may be administered at any stage, provided the milk is not intended for human consumption.

Research Evidence / Overview of Studies for Closamectin

Evidence for Management of Mixed Parasitic Infestations

Research exploring the use of Closamectin primarily centers on its application for mixed parasitic infestations in livestock. Studies have explored conditions involving several types of threats simultaneously, including trematodes (fluke), nematodes (roundworms), and arthropods (lice and mites). The main research has relied on two primary types of study design: controlled challenge trials and randomized field studies. In the challenge trials, animals were deliberately infected with target parasites, allowing researchers to explore the product under highly controlled conditions. Field studies, conversely, were applied in settings where animals had naturally acquired infections.

Studies monitored various outcomes related to systemic or functional imbalance associated with parasitic activity. Researchers examined the impact on the number of parasites present by using direct methods, such as post-mortem worm and fluke counts, which were used in the measurement of parasite numbers. They also monitored the reduction in faecal egg counts (FECRT), which reports the pattern of egg output from surviving parasites during the study period.

Findings describe patterns observed in the studies used in the regulatory assessment. These studies report how parasite numbers evolved in the observed populations. For example, some controlled trials described patterns of reduction in specific parasite life stages (e.g., late immature and mature fluke) when assessed via post-mortem counts. However, the evidence is not uniform across all targets. For instance, the research provides limited insight into the product’s ability to achieve complete elimination of certain external parasites, such as mites and lice, with some regulatory summaries noting the product only as an “aid in the control” for these targets.

Evidence for Short-Term Efficacy and Duration of Activity

Research has primarily explored short-term symptom changes and immediate results. The follow-up durations for many of the key efficacy assessments were relatively limited. Post-treatment analysis was conducted at intervals such as 14, 21, and up to 51 days in the main controlled studies. These periods reflect the short-term and intermediate changes examined in the studies.

Research examined the persistence of activity and reported patterns of anti-reinfection activity observed for up to 21 days against certain parasites, such as lungworms. This evidence contributes to the broader evidence landscape but research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

What Remains Uncertain About the Research Base

Several aspects of the product’s research base are not yet fully established. Long-term effects are not fully established, as the follow-up durations were limited to short-term and intermediate intervals. There is limited information for long-term outcomes regarding the durability of parasite clearance beyond a few months.

Studies did not include an examination of real-world performance under all conditions when assessing the pour-on formulation, as the effect of rain or adverse weather on its performance was not investigated in the efficacy studies.

Key Studies & References Veterinary Medicines Directorate Summary of Product Characteristics (SPC)

Common questions about Closamectin (FAQ)

Q: Does Closamectin treat common colds or viruses?

A: Closamectin is officially described as a fixed-combination antiparasiticide. Regulatory documents confirm that it is indicated for the management of mixed parasitic infestations in its target animal species (cattle and sheep). It is not indicated or authorized for the treatment of viral infections or common colds.

Q: Can Closamectin be taken with food?

A: The official administration guidelines for the Solution for Injection and Pour-On Solution do not include a specific requirement or restriction to administer the product alongside food.

Q: How quickly should Closamectin start working?

A: Official research supporting the product's authorization has primarily examined results at time points such as 14, 21, and 51 days post-treatment. A specific, immediate onset time (like within the first few hours) is generally not detailed in the regulatory product label.

Q: Does Closamectin cause skin sensitivity to the sun?

A: The official safety documents, which list the reported adverse reactions, do not include photosensitivity (increased skin reaction to sunlight) as a side effect.

Q: Is Closamectin associated with weight gain?

A: The officially documented adverse reaction profile includes anorexia (loss of appetite), which is categorized as a very rare event. However, weight gain is not listed as a reported adverse reaction in the regulatory documents.

Q: Does Closamectin interact with caffeine?

A: The official regulatory profile identifies specific substance categories that should not be co-administered. The regulatory documents do not list any specific interaction or restriction regarding the use of caffeine.

Q: Do food products like grapefruit affect how Closamectin works?

A: Official regulatory documents list mandatory restrictions for co-administration with certain substance categories. However, the interaction profile does not list any specific restriction or warning regarding food products like grapefruit.

Q: Is Closamectin available over the counter?

A: Closamectin is classified in official regulatory documents as a Prescription Only Medicine (POM) or an equivalent regulatory category. Its classification means the product is regulated and is not available over the counter.

Q: Why is Closamectin sometimes used instead of other treatments?

A: Closamectin is defined by its fixed combination containing two different active ingredients. This dual composition allows for simultaneous management of mixed parasitic infestations involving multiple types of parasites in a single application.

Q: What should I do if I miss a scheduled dose of Closamectin?

A: The standard administration of Closamectin is generally intended as a single, one-off treatment. Because the product is not a continuous, multi-day course of therapy, the regulatory label does not provide instructions for handling a missed dose.

Q: How is Closamectin described in official regulatory documents?

A: Official documents, such as the Summary of Product Characteristics (SPC), describe Closamectin as a veterinary medicinal product. It is classified as a fixed-combination endectocide, meaning it is designed to manage both internal and external parasites.

Q: Why does Closamectin come in different strengths?

A: The product is authorized in two main formulations: a Solution for Injection and a Pour-On Solution. These different forms require distinct concentrations of active ingredients, which are tailored to their specific route of administration and corresponding bodyweight calculations.

Q: How is Closamectin eliminated from the body?

A: Official pharmacokinetic data shows that the active ingredients, Ivermectin and Closantel, are eliminated primarily through the faeces. Trace amounts are also eliminated via urine.

Q: What is the general duration of treatment with Closamectin?

A: The standard administration pattern for the product is a single, one-off treatment. An exception is the treatment of Sheep Scab, which requires a follow-up dose of an ivermectin-only product seven days after the initial dose.

Q: Are there any known issues with taking Closamectin if I have kidney problems?

A: The official regulatory label does not list kidney problems as a formal contraindication that would prevent its use.

Q: Has Closamectin been recalled or is it currently under investigation?

A: Closamectin maintains its official marketing authorization from regulatory bodies and is currently listed as an authorized product in official government databases.

Q: Is Closamectin safe to use before surgery?

A: Official documents include a mandatory withdrawal period. The regulatory withdrawal period describes the necessary time interval between the last administration and when the animal can be slaughtered for human consumption.

Q: Can Closamectin be crushed or split?

A: Closamectin is supplied as a liquid Solution for Injection or a Pour-On Solution. It is not formulated as a tablet or capsule, and therefore the issue of crushing or splitting does not apply to this product.

Q: Are there long-term side effects associated with Closamectin use?

A: Official safety documents classify reported adverse events by frequency (e.g., Common, Very Rare). These documents do not specifically define side effects that occur only after long-term use, and research follow-up durations were limited to short-term and intermediate intervals.

Q: Can Closamectin be used during pregnancy, according to official guidelines?

A: The product may be administered to pregnant animals. However, it is contraindicated (officially prohibited) for use in any animal producing milk intended for human consumption, including heifers in the last trimester of pregnancy.

Q: Is Closamectin safe to use while breastfeeding?

A: The product may be administered to lactating animals. It is explicitly contraindicated (officially prohibited) for use if the milk produced by the animal is intended for human consumption.

Q: What is the meaning of the warning label on the Closamectin box?

A: Official warnings require the product to be kept out of the sight and reach of children and stored in its original container. Due to potential flammability risks, the label states the product is to be kept away from heat, sparks, open flames, and ignition sources.

Q: What are the most common reasons why a doctor would prescribe Closamectin?

A: According to regulatory documents, the primary indications for use are for the treatment of mixed parasitic infestations. This includes specific internal parasites, such as liver and stomach fluke and gastrointestinal roundworms, and external pests like mites and lice.

Storage and Disposal of Closamectin: Official Regulatory Requirements

The storage and disposal of Closamectin must adhere strictly to labeled conditions to ensure product stability and environmental safety.

Mandatory Storage Conditions

Stability and Disposal Rules

The official labeling mandates strict environmental precautions due to the product’s toxicity, requiring specialized waste handling and preventing contact with water courses.